|
AU2006201733A1
|
|
Process for manufacturing paclitaxel and 13-acetyl-9-dihydrobaccatin III
|
|
WO2004091506A2
|
|
Taxane-based compositions and methods of use
|
|
WO03057278A2
|
|
Drug delivery system for sustained delivery of glipizide
|
|
AU2002360816A1
|
|
Taxane based compositions and methods of use
|
|
MXPA04005901A
|
|
Taxane based compositions and methods of use.
|
|
EP1421091A1
|
|
Saccharide sulfation methods
|
|
AU4588202A
|
|
Method and compositions for treating late phase allergic reactions and inflammatory diseases
|
|
TWI255269B
|
|
Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
|
|
NZ529036A
|
|
Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
|
|
CA2434765A1
|
|
Degradation-resistant glucocorticosteroid formulations
|
|
EP1018510A1
|
|
Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
|
|
EP1462148A2
|
|
Methods and compositions for the prevention of tolerance to bronchodilators
|
|
EP1479382A1
|
|
Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
|
|
EP1634607A2
|
|
Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
|
